A practical review of prognostic correlations of molecular biomarkers in glioblastoma

Neurosurgical Focus

Volumn 38, Issue 3, 2015, Pages

  Karsy, Michael ^a   Neil, Jayson A ^a   Guan, Jian ^a   Mark, Mahan A ^a   Colman, Howard ^a,b   Jensen, Randy L ^a,b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

Biomarker; GBM; IDH1 2; MGMT; Overall survival; Progression free survival

Indexed keywords

BIOLOGICAL MARKER; DNA LIGASE; DNA METHYLTRANSFERASE; EPIDERMAL GROWTH FACTOR RECEPTOR; ISOCITRATE DEHYDROGENASE; MGMT PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN P53; PTEN PROTEIN, HUMAN; TUMOR PROTEIN; TUMOR SUPPRESSOR PROTEIN;

BRAIN NEOPLASMS; CHROMOSOME 1; CHROMOSOME 19; GENETICS; GLIOBLASTOMA; HUMAN; PROGNOSIS;

BIOMARKERS; BRAIN NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; GLIOBLASTOMA; HUMANS; ISOCITRATE DEHYDROGENASE; NEOPLASM PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; PTEN PHOSPHOHYDROLASE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 84929629151     PISSN: None     EISSN: 10920684     Source Type: Journal    
DOI: 10.3171/2015.1.FOCUS14755     Document Type: Article

References (56)

1. Beiko J, Suki D, Hess KR, Fox BD, Cheung V, Cabral M, et al: IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro Oncol 16:81-91, 2014.
2. Biernat W, Kleihues P, Yonekawa Y, Ohgaki H: Amplification and overexpression of MDM2 in primary (de novo) glioblastomas. J Neuropathol Exp Neurol 56:180-185, 1997.
3. Blough MD, Beauchamp DC, Westgate MR, Kelly JJ, Cairncross JG: Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma. J Neurooncol 102:1-7, 2011.
4. Boots-Sprenger SHE, Sijben A, Rijntjes J, Tops BBJ, Idema AJ, Rivera AL, et al: Significance of complete 1p/19q codeletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution. Mod Pathol 26:922-929, 2013.
5. Brennan C, Momota H, Hambardzumyan D, Ozawa T, Tandon A, Pedraza A, et al: Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS ONE 4:e7752, 2009.
6. Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, et al: Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 31:337-343, 2013.
7. Cancer Genome Atlas Research Network: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061-1068, 2008.
8. Carico C, Nuño M, Mukherjee D, Elramsisy A, Dantis J, Hu J, et al: Loss of PTEN is not associated with poor survival in newly diagnosed glioblastoma patients of the temozolomide era. PLoS ONE 7:e33684, 2012.
9. Clark KH, Villano JL, Nikiforova MN, Hamilton RL, Horbinski C: 1p/19q testing has no significance in the workup of glioblastomas. Neuropathol Appl Neurobiol 39:706-717, 2013.
10. Crinière E, Kaloshi G, Laigle-Donadey F, Lejeune J, Auger N, Benouaich-Amiel A, et al: MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities. J Neurooncol 83:173-179, 2007.
11. Donato V, Papaleo A, Castrichino A, Banelli E, Giangaspero F, Salvati M, et al: Prognostic implication of clinical and pathologic features in patients with glioblastoma multiforme treated with concomitant radiation plus temozolomide. Tumori 93:248-256, 2007.
12. England B, Huang T, Karsy M: Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme. Tumour Biol 34:2063-2074, 2013.
13. Felsberg J, Rapp M, Loeser S, Fimmers R, Stummer W, Goeppert M, et al: Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients. Clin Cancer Res 15:6683-6693, 2009.
14. Frederick L, Wang XY, Eley G, James CD: Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 60:1383-1387, 2000.
15. Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, et al: Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol 9:29-38, 2008.
16. Hartmann C, Hentschel B, Simon M, Westphal M, Schackert G, Tonn JC, et al: Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations. Clin Cancer Res 19:5146-5157, 2013.
17. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003, 2005.
18. Holdhoff M, Ye X, Blakeley JO, Blair L, Burger PC, Grossman SA, et al: Use of personalized molecular biomarkers in the clinical care of adults with glioblastomas. J Neurooncol 110:279-285, 2012.
19. Houillier C, Lejeune J, Benouaich-Amiel A, Laigle-Donadey F, Criniere E, Mokhtari K, et al: Prognostic impact of molecular markers in a series of 220 primary glioblastomas. Cancer 106:2218-2223, 2006.
20. Huse JT, Holland EC: Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer 10:319-331, 2010.
21. Ichimura K, Schmidt EE, Miyakawa A, Goike HM, Collins VP: Distinct patterns of deletion on 10p and 10q suggest involvement of multiple tumor suppressor genes in the development of astrocytic gliomas of different malignancy grades. Genes Chromosomes Cancer 22:9-15, 1998.
22. Ichimura K, Vogazianou AP, Liu L, Pearson DM, Bäcklund LM, Plant K, et al: 1p36 is a preferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas. Oncogene 27:2097-2108, 2008.
23. Idoate MA, Echeveste J, Diez-Valle R, Lozano MD, Aristu J: Biological and clinical significance of the intratumour heterogeneity of PTEN protein expression and the corresponding molecular abnormalities of the PTEN gene in glioblastomas. Neuropathol Appl Neurobiol 40:736-746, 2014.
24. Karsy M, Albert L, Murali R, Jhanwar-Uniyal M: The impact of arsenic trioxide and all-trans retinoic acid on p53 R273Hcodon mutant glioblastoma. Tumour Biol 35:4567-4580, 2014.
25. Karsy M, Huang T, Kleinman G, Karpel-Massler G: Molecular, histopathological, and genomic variants of glioblastoma. Front Biosci (Landmark Ed) 19:1065-1087, 2014.
26. Kita D, Yonekawa Y, Weller M, Ohgaki H: PIK3CA alterations in primary (de novo) and secondary glioblastomas. Acta Neuropathol 113:295-302, 2007.
27. Koul D: PTEN signaling pathways in glioblastoma. Cancer Biol Ther 7:1321-1325, 2008.
28. Krell D, Mulholland P, Frampton AE, Krell J, Stebbing J, Bardella C: IDH mutations in tumorigenesis and their potential role as novel therapeutic targets. Future Oncol 9:1923-1935, 2013.
29. Labussière M, Boisselier B, Mokhtari K, Di Stefano AL, Rahimian A, Rossetto M, et al: Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes. Neurology 83:1200-1206, 2014.
30. Laxton RC, Popov S, Doey L, Jury A, Bhangoo R, Gullan R, et al: Primary glioblastoma with oligodendroglial differentiation has better clinical outcome but no difference in common biological markers compared with other types of glioblastoma. Neuro Oncol 15:1635-1643, 2013.
31. Malkoun N, Chargari C, Forest F, Fotso MJ, Cartier L, Auberdiac P, et al: Prolonged temozolomide for treatment of glioblastoma: preliminary clinical results and prognostic value of p53 overexpression. J Neurooncol 106:127-133, 2012.
32. Nakamura M, Watanabe T, Klangby U, Asker C, Wiman K, Yonekawa Y, et al: p14ARF deletion and methylation in genetic pathways to glioblastomas. Brain Pathol 11:159-168, 2001.
33. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, et al: Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17:510-522, 2010.
34. Ohgaki H, Kleihues P: Genetic profile of astrocytic and oligodendroglial gliomas. Brain Tumor Pathol 28:177-183, 2011.
35. Ozawa T, Brennan CW, Wang L, Squatrito M, Sasayama T, Nakada M, et al: PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas. Genes Dev 24:2205-2218, 2010.
36. Parsons DW, Jones S, Zhang X, Lin JCH, Leary RJ, Angenendt P, et al: An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807-1812, 2008.
37. Philip R, Carrington L, Chan M: US FDA perspective on challenges in co-developing in vitro companion diagnostics and targeted cancer therapeutics. Bioanalysis 3:383-389, 2011.
38. Phillips JJ, Aranda D, Ellison DW, Judkins AR, Croul SE, Brat DJ, et al: PDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastoma. Brain Pathol 23:565-573, 2013.
39. Rich JN, Hans C, Jones B, Iversen ES, McLendon RE, Rasheed BKA, et al: Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res 65:4051-4058, 2005.
40. Ruano Y, Ribalta T, de Lope AR, Campos-Martín Y, Fiaño C, Pérez-Magán E, et al: Worse outcome in primary glioblastoma multiforme with concurrent epidermal growth factor receptor and p53 alteration. Am J Clin Pathol 131:257-263, 2009.
41. Salkeni MA, Zarzour A, Ansay TY, McPherson CM, Warnick RE, Rixe O, et al: Detection of EGFRvIII mutant DNA in the peripheral blood of brain tumor patients. J Neurooncol 115:27-35, 2013.
42. Sami A, Karsy M: Targeting the PI3K/AKT/mTOR signaling pathway in glioblastoma: novel therapeutic agents and advances in understanding. Tumour Biol 34:1991-2002, 2013.
43. Schmidt MC, Antweiler S, Urban N, Mueller W, Kuklik A, Meyer-Puttlitz B, et al: Impact of genotype and morphology on the prognosis of glioblastoma. J Neuropathol Exp Neurol 61:321-328, 2002.
44. SongTao Q, Lei Y, Si G, YanQing D, HuiXia H, XueLin Z, et al: IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma. Cancer Sci 103:269-273, 2012.
45. Stancheva G, Goranova T, Laleva M, Kamenova M, Mitkova A, Velinov N, et al: IDH1/IDH2 but not TP53 mutations predict prognosis in Bulgarian glioblastoma patients. Biomed Res Int 2014:654727, 2014.
46. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996, 2005.
47. Taylor TE, Furnari FB, Cavenee WK: Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance. Curr Cancer Drug Targets 12:197-209, 2012.
48. Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al: Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98-110, 2010.
49. Watanabe T, Vital A, Nobusawa S, Kleihues P, Ohgaki H: Selective acquisition of IDH1 R132C mutations in astrocytomas associated with Li-Fraumeni syndrome. Acta Neuropathol 117:653-656, 2009.
50. Weller M, Kaulich K, Hentschel B, Felsberg J, Gramatzki D, Pietsch T, et al: Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy. Int J Cancer 134:2437-2447, 2014.
51. Wemmert S, Ketter R, Rahnenführer J, Beerenwinkel N, Strowitzki M, Feiden W, et al: Patients with high-grade gliomas harboring deletions of chromosomes 9p and 10q benefit from temozolomide treatment. Neoplasia 7:883-893, 2005.
52. Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, et al: NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 27:5874-5880, 2009.
53. Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, et al: Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 13:707-715, 2012.
54. Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, Bigner DS, et al: Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci U S A 89:2965-2969, 1992.
55. Zhao J, Ma W, Zhao H: Loss of heterozygosity 1p/19q and survival in glioma: a meta-analysis. Neuro Oncol 16:103-112, 2014.
56. Zheng H, Ying H, Yan H, Kimmelman AC, Hiller DJ, Chen AJ, et al: p53 and PTEN control neural and glioma stem/progenitor cell renewal and differentiation. Nature 455:1129-1133, 2008.